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Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines
proliferation/migration choices in Ewing sarcoma cells
G-A Franzetti1,2,10, K Laud-Duval1,2,10, W van der Ent1,2,3, A Brisac1,2, M Irondelle1,4,5, S Aubert6, U Dirksen7, C Bouvier8, G de Pinieux9,
E Snaar-Jagalska3, P Chavrier1,4 and O Delattre1,2
Ewing sarcoma is characterized by the expression of the chimeric EWSR1-FLI1 transcription factor. Proteomic analyses indicate that
the decrease of EWSR1-FLI1 expression leads to major changes in effectors of the dynamics of the actin cytoskeleton and the
adhesion processes with a shift from cell-to-cell to cell-matrix adhesion. These changes are associated with a dramatic increase of
in vivo cell migration and invasion potential. Importantly, EWSR1-FLI1 expression, evaluated by single-cell RT-ddPCR/
immunoﬂuorescence analyses, and activity, assessed by expression of EWSR1-FLI1 downstream targets, are heterogeneous in cell
lines and in tumours and can ﬂuctuate along time in a fully reversible process between EWSR1-FLI1high states, characterized by
highly active cell proliferation, and EWSR1-FLI1low states where cells have a strong propensity to migrate, invade and metastasize.
This new model of phenotypic plasticity proposes that the dynamic ﬂuctuation of the expression level of a dominant oncogene is
an intrinsic characteristic of its oncogenic potential.
Oncogene advance online publication, 30 January 2017; doi:10.1038/onc.2016.498
INTRODUCTION
Ewing sarcoma, the second most frequent primary bone tumour
among teenagers and young adults, constitutes a highly
aggressive tumour1 characterized by early metastatic spread.2
Although current treatment using chemotherapy in addition to
local treatment has increased the 5-year survival rate to around
70%,3 the clinical outcome for patients who present metastatic
disease, initially or at relapse, remains poor with a long-term
survival rate of only 20%.4
In 85% of cases, Ewing sarcoma is characterized by the
expression of the EWSR1-FLI1 chimeric protein resulting from
the chromosomal translocation t(11;22)(q24:q12), which links the
transcription regulating domain of EWSR1 to the ETS DNA-binding
domain of FLI1.5 The EWSR1-FLI1 fusion protein behaves as an
aberrant transcriptional factor modulating the expression of
speciﬁc target genes.6 EWSR1-FLI1 expression promotes oncogen-
esis of Ewing sarcoma as demonstrated by its ability to transform
NIH3T3 cells to form tumours in immunodeﬁcient mice.7,8
Moreover, the invalidation of EWSR1-FLI1 expression by speciﬁc
si/shRNAs induces an arrest of Ewing sarcoma cell line prolifera-
tion in vitro and in vivo (reviewed in Toomey et al.9). However, very
few reports have yet addressed the possible role of EWSR1-FLI1 on
the mechanisms of metastatic spread and the metastatic process
underlying sarcoma remains largely unknown.
Recently, two studies have proposed non-exclusive models
of metastatic dissemination for Ewing sarcoma. Krook and
colleagues10 have underlined the inﬂuence of various cell stresses
such as hypoxia, pressure of microenvironment and privation of
growth factors to upregulate the CXCR4 chemokine receptor and
hence promote migration and invasion properties of Ewing cells.
A second model reported as a ‘passive/stochastic metastasis
model’ has also been proposed to account for the strong
propensity of Ewing cells to disseminate.11,12 The authors show
that EWSR1-FLI1 expression loosens cell adhesion, and they
therefore propose that poorly attached Ewing cells passively
disseminate in the circulation.11,13
Here we show that the heterogeneity of EWSR1-FLI1 expression
may constitute an essential element of the multistep metastatic
process. Indeed, we propose that the cell-to-cell ﬂuctuations of
EWSR1-FLI1 expression level constitute a major source of
phenotypic heterogeneity and enable individual Ewing cells to
switch from proliferation to migration states.
RESULTS
Proteomic analyses of EWSR1-FLI1-regulated proteins
While numerous reports have investigated the transcriptional
consequences of the modulation of EWSR1-FLI1 in Ewing sarcoma
cells, the Ewing cell proteome upon EWSR1-FLI1 modulation still
remains mostly unexplored. In this objective, we developed
two proteomic approaches based on 2D-DIGE and SILAC to
evaluate EWSR1-FLI1-dependent proteome by mass spectrometry
(Supplementary Figures S1A and B). Two different cell systems
were used. One consisted in lentivirus-mediated shRNA silencing
of EWSR1-FLI1 in Ewing cell lines; the other was based on the
construction of clones expressing a doxycycline (DOX) inducible
shRNA against the EWSR1-FLI1 fusion. Inducible EWSR1-FLI1
expressing systems were obtained for the A673 (shA673-1c,
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described in Tirode et al14) and SK-N-MC cells lines (shSK-E17T). In
the presence of DOX, the expression level of the EWSR1-FLI1
protein was decreased by 54 and 36% in the shA673-1c and shSK-
E17T clones, respectively (Figure 1a). The inhibition of EWSR1-FLI1
is associated with a strong decrease of cell proliferation14 without
cell mortality.15 EWSR1-FLI1 re-expression by removal of DOX
restores cell proliferation (Supplementary Figures S2A and B).
Following lentivirus-mediated silencing of EWSR1-FLI1 in the
A673 cell line, 2D-DIGE was performed comparing Cy3- and Cy5-
labelled A673 infected with either a control shRNA (EWSR1-
FLI1high cells) or an EWSR1-FLI1-speciﬁc shRNA (EWSR1-FLI1low
cells), respectively. A total of 185 differential spots were picked
and further investigated by MS/MS. We identiﬁed 175 EWSR1-FLI1-
modulated proteins (fold change41.5; Po0.01; Supplementary
Table S1). Ingenuity Pathway Analysis was used to mine the data.
It showed that the reorganization of actin cytoskeleton and the
regulation of actin-based motility by Rho were among the most
highly signiﬁcant differential pathways between both conditions
(Supplementary Figure S1C). Differentially expressed proteins
include coﬁlin-1 (CFL1), proﬁlin-2 (PFN2) and gelsolin (GSN) that
are involved in the assemblage of actin cytoskeleton; α-actinin
(ACTN4), moesin (MSN), radixin (RDX) and vinculin (VCL), which are
actin-binding and cytoskeleton-linking proteins; and myosin light
chain phosphorylatable (MYLPF), myosin light chain 12A (MYL12A)
as well as myosin light chain 6 (MYL6) that participate to
the contractile forces necessary to migration processes
(Supplementary Figure S1D). These 2D-DIGE results were fully
conﬁrmed for the three proteins that were tested by western blot
(CFL1, VCL, PFN2 in Supplementary Figure S1E).
In addition to 2D-DIGE data, SILAC experiments were performed
on the shA673-1c clone in order to identify membrane proteins
modulated by EWSR1-FLI1. Membrane proteins from untreated
(EWSR1-FLI1high) or DOX-treated (EWSR1-FLI1low) shA673-1c cells
were grown in the presence of heavy or light molecular weight
forms of arginine and lysine, respectively. Ingenuity Pathway
Analysis of the 131 SILAC-quantiﬁed proteins (Supplementary
Table S2) allowed us to highlight an enrichment in proteins
involved in cell morphology and migration in full agreement with
2D-DIGE data, but also proteins involved in cell interaction
processes (Supplementary Figure S1F). Indeed, among this list,
at least 10 EWSR1-FLI1-modulated proteins (FC41.25) are
known to be involved in cell–cell or cell–matrix interactions
(Supplementary Figure S1G). Interestingly, EWSR1-FLI1 strongly
upregulates plakophilin (PKP1) and desmoplakin (DSP), two
essential components of the specialized cell-to-cell interaction
desmosome structure. At the opposite, it considerably down-
regulates cell–matrix interaction proteins such as the integrins
α1 (ITGA1), α4 (ITGA4), β1 (ITGB1) that are hence highly expressed
in EWSR1-FLI1low cells. As for 2D-DIGE, a subset of the variations
observed with the SILAC approach was conﬁrmed by western blot
in A673, SK-N-MC, EW7 or TC71 cells (Supplementary Figures S1H
and I). Further investigating transcriptomics data,16 we also
identiﬁed intercellular adhesion molecule 1 (ICAM1) and two tight
junction proteins, claudin-1 (CLD1) and occludin (OCL), as highly
downregulated by EWSR1-FLI1. Altogether, these data strongly
suggest that EWSR1-FLI1low cells are less cohesive with more cell–
matrix interactions and a stronger cytoskeleton organization as
compared to EWSR1-FLI1high cells.
We also conﬁrmed that these variations of protein levels are
associated with profound modiﬁcations of the cytoskeleton.11,17
Indeed, we compared the organization of the actin stress ﬁbres in
shA673-1c and shSK-E17T clones after 10 days of DOX treatment.
Untreated cells have the small round cell morphology typical of
the Ewing sarcoma, with thin, short and disorganized actin stress
ﬁbres. At the opposite, DOX-treated cells harbour a much larger
area of spreading, associated to long and parallel actin stress
ﬁbres (Figures 1b and c).
To further explore the phenotype of EWSR1-FLI1low cells, we
studied migration and invasion properties of Ewing cells in three-
dimensional models. Multicellular spheroids, generated by the
natural aggregation of shA673-1c and shSK-E17T cells, pretreated
or not by DOX for 10 days, were included in a collagen-matrix and
cell migration was monitored by time-lapse video microscopy
(Figure 1d). After 24 h, DOX-untreated spheroids presented a
stable surface with only very few cells (1 or 2 by ﬁeld) escaping
from the spheroid to migrate through the three-dimensional
matrix (Supplementary Movie S1, upper panel). At the opposite, we
observed a very rapid migration of cells outside the DOX-treated
spheroids, with important protrusions (Supplementary Movie S1,
lower panel). After 24 h, in DOX-treated conditions, the collagen-
matrix was invaded by cells, through either individual (shA673-1c
+DOX) or more collective cell movements (shSK-E17T+DOX).
To conﬁrm three-dimensional migration and invasion in vivo, we
used a recently established model of zebraﬁsh embryo
xenotransplantation18 and the shA673-1c clone, modiﬁed to
stably express mCherry protein. After 10 days of DOX-treatment,
EWSR1-FLI1low and EWSR1-FLI1high cells were injected into the yolk
of 2-days-old embryos. After 4 days, in the presence (n= 22
embryos) or absence (n= 27) of DOX in the egg water, invasion
and proliferation of tumour cells were evaluated by confocal
microscopy and cumulative results of each embryo are repre-
sented in a scatter plot (Figure 1e), where each dot represents a
ﬂuorescent cluster of tumour cells. For invasion, DOX-treated cells
displayed a fourfold increase in the cumulative migration distance
from injection site (Po0.001). To determine tumour burden per
embryo, the number of clusters was multiplied by the average size
of clusters. Due to the increased spreading of the cells, more
individual clusters were found in the DOX-treated group. However,
cluster diameters of the DOX-treated versus untreated group were
generally lower (from 27 to 51 μm and 33 to 78 μm, respectively).
Resultantly, a signiﬁcant reduction of the tumour burden was
observed in DOX-treated as compared to untreated cells/embryos
(Figure 1f).
Taking together with our molecular data, these in vitro and
in vivo observations demonstrated clearly that EWSR1-FLI1low cells
display proteomic changes associated with an active migration
mechanism, which is uncoupled from proliferation of EWSR1-
FLI1high cells.
EWSR1-FLI1 expression is heterogeneous in Ewing cell lines
Our results indicate that the experimental modiﬁcation of EWSR1-
FLI1 expression level is sufﬁcient to control the proliferation and
migration properties of Ewing cells. Thus, EWSR1-FLI1high cells
proliferate, whereas EWSR1-FLI1low cells instead have a strong
propensity to migrate. An important question is therefore to
deﬁne how much this experimental observation is relevant in the
context of the human malignancy.
We ﬁrst explored whether the expression levels of EWSR1-FLI1
transcript and protein are variable from one cell to the other in cell
lines or in tumours. We quantiﬁed the absolute number of EWSR1-
FLI1 and RPLP0 mRNA molecules at the single cell level through
droplet digital PCR (single cell RT-ddPCR) in three Ewing cell lines
(A673, SK-N-MC and TC71), as well as in DOX-treated/untreated
shA673-1c and shSK-E17T clones (Supplementary Figure S3A). This
showed that cells with an equivalent number of the housekeeping
RPLP0 mRNA molecules may display important variations of
EWSR1-FLI1 (Supplementary Figure S3B). Using RPLP0 to normalize
EWSR1-FLI1 expression, we observed important variations of
EWSR1-FLI1 expression within and across the different cell lines
(Figure 2a). Importantly, highly signiﬁcantly different EWSR1-FLI1
mean expression values (Po0.001) were observed between
DOX-treated and untreated shA673-1c or shSKE-17T cells hence
providing a validation of single cell measurements. Using the
interquartile range of the normalized expression median (EWSR1-
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Figure 1. EWSR1-FLI1low cells demonstrate increased migration and invasion in three-dimensional matrix and in zebraﬁsh. (a) Western blot,
(b) phalloidin-stained actin cytoskeleton and (c) measure of cell area of shA673-1c and shSK-E17T clones treated for 10 days (+DOX) with
1 μg/ml DOX or untreated (-DOX) (n= 15 per group). Scale bars represent 20 μm. Error bars represent s.e.m. DOX-treated/untreated cells were
compared using Welch t-test (***Po0.001). See also Supplementary Figures S1 and S2, Supplementary Tables S1 and S2. (d) Three-
dimensional collagen-I multicellular spheroid invasion assay with shA673-1c and shSK-E17T spheroids prepared by the hanging droplet
method. 24-h videos were acquired and three time-points are shown. Red dotted lines represent the initial spheroid perimeter. Scale bars
represent 100 μm. See also Supplementary Movie S1. (e) Representative pictures of zebraﬁsh xenotransplantation model 4 days post-injection
and cumulative results of migration distance of shA673-1c/mCherry cells, DOX-treated or -untreated, from implantation site (X) into the yolk
sac for all zebraﬁsh embryos, where each colour represents an individual embryo, and each dot a cluster of one or more tumour cells. Scale
bars represent 500 μm. (f) Mean cumulative distance of migration and relative tumour burden of shA673-1c/mCherry cells (n= 22 to 27 ﬁsh
per group), error bars represent 1-way ANOVA with Bonferroni post-test (*Po0.05, ***Po0.001).
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FLI1/RPLP0 ratio) of DOX-treated shA673-1c and shSK-E17T clones,
we could deﬁne an upper threshold for EWSR1-FLI1low status.
Interestingly, it is clearly apparent that EWSR1-FLI1low subpopula-
tions of cells can be observed spontaneously in each of the A673,
SK-N-MC and TC71 Ewing cell lines. The quantiﬁcation of the
EWSR1-FLI1 protein expression level was also performed using
three-dimensional deconvolution microscopy associated with
ImageJ software of Ewing cell lines immunostained with an FLI1
antibody (Figure 2b, Supplementary Figure S3C), knowing these
Ewing do not express wild-type FLI1. For each cell, the FLI1 signal
was normalized by the corresponding DNA signal obtained by
DAPI staining.19,20 As observed with the measurement of the
EWSR1-FLI1 mRNA, this experiment fully conﬁrmed the presence
of an EWSR1-FLI1low subpopulation in A673 and TC71 cell lines
(Figure 2c).
We then wished to have a more direct measure of EWSR1-FLI1
activity. EWSR1-FLI1 is a transcription factor that can act as an
activator or as a repressor depending on the regulated genes. We
chose to use ICAM1, the expression of which is inhibited by
EWSR1-FLI1 (Supplementary Figure S1H and in Tirode et al14).
This protein can be very sensitively detected by FACS analysis and
can be used for sorting living cells. A mostly negative expression
of ICAM1 was observed by FACS in A673 cells with only a small
component of cells being ICAM1 positive (Figure 2d). To assess
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whether this variable expression of ICAM1 could be related to a
low EWSR1-FLI1 expression, we isolated the ICAM1− and ICAM+
subpopulations and analysed the mRNA expression of IGFBP3 and
LOX, two targets that are known to be directly repressed by
EWSR1-FLI121–23 (Supplementary Figure S4). Should ICAM1
expression be dependent on EWSR1-FLI1, we would expect
IGFBP3 and LOX to be also downregulated in ICAM1− cells
whereas an EWSR1-FLI1-independent variability of ICAM1 would
not be associated with coordinated variation of LOX and IGFBP3.
We observed that the ICAM1 but also the IGFBP3 and LOX
transcripts are strongly upregulated in the ICAM1+ subpopulation,
a result in full consistency with the three genes being coordinately
regulated by EWSR1-FLI1 (Figure 2e). These data indicate that the
expression levels of EWSR1-FLI1 downstream targets are hetero-
geneous in Ewing cell lines and further suggest that this
heterogeneity results from cell-to-cell variation in EWSR1-FLI1
activity.
We then addressed the question of the ability of the Ewing cells
to switch from an EWSR1-FLI1low to an EWSR1-FLI1high state and
vice versa. ICAM1− and ICAM1+ subpopulations were ﬂow-sorted
and grown in culture. A new FACS analysis was performed 20 and
38 days after cell sorting and revealed that both cell populations
have the ability to regenerate most of the initial heterogeneity
therefore indicating that EWSR1-FLI1low can give rise to EWSR1-
FLI1high cells and vice versa (Figure 2f).
As LOX is a known downstream repressed target of EWSR1-
FLI123 (Supplementary Figure S4) that can be easily detected by
immunohistochemistry, we used it as a surrogate marker of
EWSR1-FLI1 activity to screen Ewing cell lines and primary
tumours. As expected, in A673 and SK-N-MC cell lines, most cells
do not express the LOX protein, and only very few cells (o0.1%)
present intense LOX expression (Figure 3a). Interestingly, while
LOX-negative cells form clusters of inter-adhesive cells, the LOX-
positive cells are isolated and present an important area of
spreading. A double staining of LOX and actin further showed that
these LOX positive cells were characterized by the presence of
strong and robust actin stress ﬁbres and well-spread shape
(Figures 1b and c), all features of EWSR1-FLI1low cells (Figure 3a).
We next analysed LOX expression in shA673-1c-derived xenografts
(described in Postel-Vinay et al.16 and Franzetti et al.24). When
xenografted mice were treated with DOX for 10 days, tumours
presented an intense LOX nuclear/peri-nuclear staining (Figure 3b)
hence conﬁrming in vivo the negative regulation of LOX
expression by EWSR1-FLI1. In contrast, xenografts from untreated
mice were globally negative for LOX staining, and only a very
small number of LOX positive tumour cells was found. Collectively,
these data conﬁrmed the rarity of LOX positive cells in Ewing cell
lines and xenograft models, and further suggested that these
LOX-positive cells correspond to EWSR1-FLI1low cells. To further
evaluate EWSR1-FLI1 heterogeneity in human tumours, we
screened a large cohort of 294 Ewing sarcoma patient-derived
samples on four series of tissue microarrays (TMAs) by immuno-
histochemistry. We detected LOX positive Ewing cells in 69
samples. Precise quantiﬁcation on a subset of eight Ewing
sarcoma samples revealed 0.97–1.6% of LOX positive cells
(Figure 3c).
Altogether these experiments indicate that the presence and
activity of EWSR1-FLI1 can quantitatively and qualitatively vary
with time within Ewing cells. The assessment of EWSR1-FLI1
expression and activity also documents the spontaneous presence
of small fraction of EWSR1-FLI1low cells in Ewing sarcoma cell lines,
xenografts and tumours.
The EWSR1-FLI1low→ high transition increases lung metastasis
in vivo.
Above described experiments indicate that Ewing cell populations
are characterized in vitro and in vivo by cell-to-cell heterogeneity
of EWSR1-FLI1 expression. The observation that EWSR1-FLI1low
cells have increased migration and invasion capacities, suggests
they may have a critical role in the metastasis spread. Interestingly,
Chaturvedi and colleagues11 have shown that EWSR1-FLI1-
knocked-down Ewing cells have increased propensity for lung
seeding in vivo. But the ability of these cells to form metastases
was not tested. We therefore further evaluated the ability of
EWSR1-FLI1low cells to develop in metastasis upon recovery of full
EWSR1-FLI1 expression. We took advantage of the reversibility of
the knock-down of EWSR1-FLI1 in shA673-1c cells upon DOX
withdrawal (Supplementary Figure S2). Indeed, when DOX is
removed from the medium of shA673-1c cells pre-treated by DOX
during 10 days, full re-expression of EWSR1-FLI1 and recovery of
proliferation potential were observed. To study the metastatic
potential of cells with the EWSR1-FLI1low→ high transition in vivo,
shA673-1c cells stably expressing green ﬂuorescent protein (GFP)
were DOX-pretreated in vitro for 10 days to achieve a low EWSR1-
FLI1 expression and then injected into mouse tail vein (EWSR1-
FLI1low→high group; Figure 4a). To allow the re-expression of
EWSR1-FLI1, no DOX was given to the drinking water of mice. As a
control, the same experiment was conducted using DOX-
untreated GFP expressing shA673-1c cells (EWSR1-FLI1high group).
After 4 weeks, mice were sacriﬁced and lungs were collected then
screened for GFP-positive nodules (Figure 4b). CD99 staining
was also used as a positive surrogate marker of EWSR1-FLI1
expression.24 GFP/CD99/EWSR1-FLI1 cells were detected in 7/8
mice injected with EWSR1-FLI1low cells but in only 3/8 mice
injected with EWSR1-FLI1high cells (Figure 4c). Moreover, the
number and the size of nodules (Figure 4d) were very signiﬁcantly
higher in the EWSR1-FLI1low→ high group as compared to the
EWSR1-FLI1high group. Indeed, we counted 48 nodules (41
Figure 2. EWSR1-FLI1 expression is heterogeneous in Ewing cell lines. (a) Gene expression proﬁling at the single cell level by RT-ddPCR of
EWSR1-FLI1 and RPLP0 mRNA. Representation of EWSR1-FLI1/RPLP0 ratio in A673, SK-N-MC and TC71 Ewing cell lines; and in shA673-1c, shSK-
E17T, shA673-1c+DOX, and shSK-E17T+DOX clones (inducible systems), each dot represents one cell. Bars represent median with interquartile
range. The EWSR1-FLI1low threshold is deﬁned by the upper limit of the interquartile range of DOX-treated cells. DOX-treated/untreated cells
were compared using Wilcoxon test (***Po0.001). See also Supplementary Figure S2. (b) Protein quantiﬁcation by immunoﬂuorescence using
three-dimensional deconvolution microscopy completed with ImageJ quantiﬁcation at the single cell level of EWSR1-FLI1 (FLI1) normalized to
DNA content (DAPI). Three-dimensional microscopy was performed on Eclipse 90i upright microscope on Nikon Imaging centre (Institut Curie,
Paris, France) with a 0.2 μm step for 3D stack and a X100 NA 1.4 oil-immersion objective. The deconvolution of each image stacks was
performed automatically using an iterative 7 and algorithm Meinel50 by PICT-IBiSA imaging facility of the Curie Institut, Paris. Scale bar
represents 10 μm (c) Representation of EWSR1-FLI1/DAPI ratio in A673 and TC71 Ewing cell lines; and in shA673-1c and shA673-1c+DOX
clones (inducible systems), each dot represents one cell. Quantiﬁcation experiments of the shA673 clone in the /+ DOX conditions were
repeated three times with fully consistent results showing highly signiﬁcant differences in the quantiﬁcation of the speciﬁc EWSR1-FLI1
staining between both conditions. Bars represent median with interquartile range. The EWSR1-FLI1low threshold is deﬁned by the upper limit
of the interquartile range of shA673-1c+DOX cells. DOX-treated/untreated cells were compared using Wilcoxon test (***Po0.001).
(d) Characterization of ICAM1− and ICAM1+ subpopulations by FACS analysis of A673 cell line stained with APC anti-ICAM1 (1:500, Biolegend,
APC anti-CD54 HA58) and (e) mRNA expression analysis by RT-qPCR of direct EWSR1-FLI1-targets, data are represented as mean +/− s.e.m.
(f) Characterization of ICAM1− and ICAM1+ subpopulations at day 0, 20 and 38 days post-sorting.
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Figure 3. Downstream markers of EWSR1-FLI1 activity conﬁrm the presence of EWSR1-FLI1low subpopulation. (a) Immunoﬂuorescence of LOX
(EWSR1-FLI1-downregulated target) and actin cytoskeleton in A673 and SK-N-MC cell lines. Images were acquired using upright wideﬁeld
Apotome microscope (Zeiss, Marly-Le-Roi, France) equipped with a Coolsnap HQ2 camera through a x63 NA 1.4 oil-immersion objective lens
and driven by Axiovision software (Zeiss). White arrows point the cells of interest, exhibiting LOX expression associated to an important cell-
spreading and a well-organized actin stress ﬁbre cytoskeleton. Scale bars represent 20 μm. (b) IHC of LOX in shA673-1c+/−DOX xenografts.
Black arrows indicate the cells of interest. Right panels represent enlargement of left panels. Scale bars represent 50 μm. (c) IHC and
quantiﬁcation of LOX in eight representative samples from Ewing tumours TMA. Black arrows point cells expressing LOX. Scale bars represent
20 μm. Error bars mean s.d.
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tumours 42000 μm2; 7 tumours o2000 μm2), against only six
moderate-to-important nodules for the EWSR1-FLI1high group.
Collectively, these data indicate that a low EWSR1-FLI1
expression strongly increases cell seeding in the lung that
may subsequently evolve into a metastasis upon EWSR1-FLI1
re-expression.
DISCUSSION
In this study, differential quantitative mass spectrometry analyses
based on 2D-DIGE and SILAC proteomic approaches reveal a
strong inﬂuence of EWSR1-FLI1 on the expression of proteins
involved in cell cytoskeleton structure and cell adhesion. Indeed,
the knockdown of EWSR1-FLI1 is associated with the increase of
actin-binding proteins implied in cell contractility (MYL6, MYL12A,
MYLPF), cytoskeleton assembly and maintenance (ACTN4, CFL1,
GSN, MSN, PFN2, RDX, VCL), but also the decrease of cell–cell
adhesion proteins as tight junctions (CLD1, OCL) and desmosome
(DSP, PKP1) family proteins. At the opposite, we observed the
increase of integrins (ITGA1, A4, B1, B5) proteins, crucial
component of cell–matrix interactions.
These modiﬁcations are associated to major phenotypic
changes. Indeed, the invalidation of EWSR1-FLI1 expression
(EWSR1-FLI1low cells) induced increased three-dimensional migra-
tion and invasion properties, as demonstrated here by spheroids
culture embedded in three-dimensional collagen-matrix and
zebraﬁsh xenotransplantation models. Moreover, tail vein injec-
tions of EWSR1-FLI1low cells show that these cells can seed in the
lung and then grow into metastases when allowed to re-express
EWSR1-FLI1. This process is much less efﬁcient when it is
conducted with EWSR1-FLI1high cells. Our observation does not
rule out previous hypotheses on the possible role of EWSR1-FLI1
to loosen cell–cell adhesion and facilitate detachment of Ewing
cells from the main tumour mass to migrate into the blood
stream.11 Obviously, the experimental procedure that is based on
injection of cells into the tail vein omits this initial ‘detachment’
step of the metastatic process. Hence, passive detachment of
EWSR1-FLI1high and active migration of EWSR1-FLI1low cells may
concurrently lead to the presence of Ewing cells into the blood
stream. Yet, our results indicate that exit from the blood stream
and attachment in distant sites may be strongly facilitated in the
context of EWSR1-FLI1low cells. Our experiments also show that
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Figure 4. The EWSR1-FLI1low→ high transition increases seeding in lung and colonization in vivo. (a) DOX-pre-treated (EWSR1-FLI1 low→ high
group) or untreated (EWSR1-FLI1high group) shA673-1c/GFP cells were injected in the mouse tail vein. During the experiments, no DOX was
given to mice to enable EWSR1-FLI1 re-expression in the DOX-pre-treated group. (b) HES, GFP, CD99 and EWSR1-FLI1 staining on slides of lung
from mice injected with shA673-1c/GFP-DOX-pre-treated clone and sacriﬁced after 4 weeks. Lung cryosections of 6 μm were prepared at
different depth with a cryostat at − 20 °C (Microm HM550). Ewing cells were revealed by positive GFP and CD99 immunostaining as described
in Franzetti et al.24 Section was scanned with Ultra-Fast Scanner (UFS, Philips). Scale bars represent 50 μm. (c) Percentage of mice positive for
GFP/CD99 lung nodules in EWSR1-FLI1high group or EWSR1-FLI1low→high group, compared using a Fisher’s exact test (*Po0.05, ***Po0.001).
(d) Number of GFP/CD99 lung nodules by group with lung nodules size distribution, measured with Image Management System (Philips
Digital Pathology) and compared using a Mann–Whitney test.
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EWSR1-FLI1low cells that can seed in the lung also maintain a
potential for growth upon EWSR1-FLI1 re-induction. In vitro and
in vivo zebraﬁsh experiments clearly document the inverse
relationship between migration and growth in Ewing sarcoma
cells. While EWSR1-FLI1low cells migrate but have very slow
proliferation rate, EWSR1-FLI1high cells proliferate but have a much
slower capacity to migrate (as illustrated in Figure 5).
These experimental data led us to investigate the heterogeneity
of EWSR1-FLI1 expression in Ewing cell lines and tumours. Single
cell RT-ddPCR and immunoﬂuorescence experiments in different
Ewing cell lines clearly show that the levels of expression of the
EWSR1-FLI1 transcript and protein are heterogeneous from one
cell to the other. Interestingly, Ewing cell lines derived from
metastasis (SK-N-MC25 and TC7126) displayed more EWSR1-FLI1low
cells as compared to the A673 cell line derived from a local
tumour.27 Moreover, the TC71 mouse xenografts are associated
with metastases,28 to our knowledge no A673 metastases have
ever been published nor have been observed in our laboratory.
To further investigate this heterogeneity, we reasoned that
expression levels of well-documented EWSR1-FLI1 targets may
constitute instrumental witnesses of EWSR1-FLI1 activity in each
cell. We choose to use EWSR1-FLI1-repressed genes as their
expression in EWSR1-FLI1low cells lead to very clear mRNA or
protein signals. The strong positive co-staining of LOX with well-
organized actin stress ﬁbres, as well as the co-expression of
ICAM1, LOX and IGFBP3, all markers that are inhibited by EWSR1-
FLI1, document the low activity of this oncoprotein in a subset of
cells. This heterogeneity of EWSR1-FLI1 activity is also highly
suspected in tumours as a small subset of LOX-positive cells can
be detected in a signiﬁcant proportion of cases. Interestingly, LOX,
which is used here as a surrogate of EWSR1-FLI1 expression, may
also have an active role in the metastatic process. Indeed, LOX is
described as a protein implicated in migration, cellular invasion
and the metastasis.29 Recently, it was demonstrated in a subtype
of breast tumours that LOX secretion by the cancer cells induces
the formation of osteolytic lesions and may drive the formation of
a pre-metastatic niche in bones facilitating the metastasis
formation.30 It may be tempting to speculate that EWSR1-FLI1low
cells expressing LOX could facilitate the degradation and invasion
of bone, the usual primary site of Ewing sarcoma, and facilitate the
formation of pre-metastatic lesions in lung. In this respect, it will
be extremely interesting to assess whether the number of LOX-
positive cells correlate with the presence of metastases once
clinical data from the patients will be released.
An important issue is how much the EWSR1-FLI1low and EWSR1-
FLI1high states are stable or can ﬂuctuate from one to the other.
Indeed, the slow proliferation of EWSR1-FLI1low cells constitutes a
competitive disadvantage with respect to the high proliferation
rate of EWSR1-FLI1high cells. The most likely hypothesis to account
for the coexistence of these two states is that the expression level
of EWSR1-FLI1 may dynamically ﬂuctuate along time in the same
cell. The isolation and regrowth of EWSR1-FLI1low and EWSR1-
FLI1high cell populations through ICAM1 heterogeneity expression
enable to observe in both cases a spontaneous regeneration of
the initial heterogeneity of the cell population. Such dynamic and
reversible switch between two different proliferative states has
been clearly documented in human melanoma cells.31,32 Dynamic
variation of the expression of the JARID1B gene was shown
to be responsible for the coexistence of a minor JARID1Bhigh
low doubling time component and a main highly proliferative
JARID1Blow compartment, both cell populations being essential to
maintain tumour growth.32 Neuroblastoma, a pediatric tumour,
also presents a reversible phenotypic heterogeneity from an
adherent phenotype to a highly migratory and invasive cell type
under stress exposure.33,34
Another important question is the mechanisms of EWSR1-FLI1
ﬂuctuation. Stochastic, cell-autonomous or non-cell-autonomous
mechanisms may be involved. While the EWSR1-FLI1 variations
spontaneously observed in cell lines, in the absence of any stromal
cells, support a role for the two ﬁrst mechanisms, the impact of
the microenvironment may also be crucial in vivo. Indeed, tumour
cell plasticity has been shown to enable tumour cells to adapt to
their environment by reversible adaptive phenotypic transforma-
tion and/or turning on and off speciﬁc markers.35 In Ewing
sarcoma, few studies have yet investigated the inﬂuence of micro-
environmental factors on the expression of EWSR1-FLI1 transcript
or protein. However, starvation of basic ﬁbroblast growth factor by
a neutralizing antibody induced a downregulation of EWSR1-FLI1
protein expression.36 Moreover, hypoxia transiently modulates the
expression of EWSR1-FLI1 and the malignant properties of Ewing
cells.37 Thus, according to cell localization and stress exposure in
tumour, the EWSR1-FLI1 expression could be differentially
modulated and consequently induce a phenotypic transition from
proliferation to invasiveness.
In many tumour types the metastatic spread is suggested to be
driven or at least favoured by the accumulation of genetic
alterations that progressively provide the cancer cells the
functional ability to escape from the primary mass and seed in
distant sites. In Ewing sarcoma, different groups have recently
described the paucity of secondary genetic alterations, in addition
to the primary EWSR1-FLI1 genetic lesion.38–40 Though STAG2 and
TP53 mutations are associated with a more aggressive disease,
their low frequency cannot account for the much more frequent
occurrence of metastases.41 The data presented here indicate that
cell-to-cell variation of the expression level of EWSR1-FLI1 as a
consequence of cell autonomous or non-autonomous mechan-
isms may constitute a critical component of the metastatic
process. Importantly, this observation may be of high clinical
importance as current therapies are directed against highly
proliferative cells and as novel therapies that target EWSR1-FLI1
are currently being developed.42–44 These therapies are expected
to be poorly efﬁcient against the EWSR1-FLI1low cell population,
which may suggest to associate to such treatments inhibitors of
the migration and invasive processes.
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Figure 5. Model of Ewing cells dissemination based on cell-to-cell
heterogeneity of EWSR1-FLI1 expression. In this model, undiffer-
entiated EWSR1-FLI1high cells proliferate with robust cell–cell
adhesion, whereas mesenchymal-like EWSR1-FLI1low cells migrate
and invade environment through important cell–matrix interactions.
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METHODS
Three-dimensional collagen I multicellular spheroid invasion
assays
Multicellular spheroids of Ewing cells were prepared by the hanging
droplets method45,46 using 4 × 103 cells in 20-μl droplets of culture
medium with 10% FBS. After 3 days of natural aggregation by gravity,
spheroids were collected and embedded in 60-μl collagen matrix onto
glass-bottom dishes.
Zebraﬁsh embryo xenotransplantation
Around 500 shA673-1c/mCherry cells were injected into the yolk as
described.18,47 Larvae with regular developmental phenotypes were maintained
at 34 °C in 60 μg/ml Instant Ocean eggwater, supplemented if necessary
with 20 μg/ml DOX. After 4 days, embryos were ﬁxed overnight in 4%
paraformaldehyde at 4 °C. Embryos were imaged in glass-bottom 96-well plates
using a NIKON3 confocal microscope. Image processing was performed with
ImageJ 1.43 (NIH). ImagePro Analyzer 7.0 (Media Cybernetics, Rockville, MD,
USA) analysis was performed as described previously.48 Zebraﬁsh were handled
compliant to local animal welfare regulations and maintained according to
standard protocols (www.ZFIN.org).
Single cell reverse transcriptase droplet digital PCR (RT-ddPCR)
Cells were FACS-sorted (MoFlo Astrios, Beckman Coulter) and dispensed
individually in 96-well plates (MicroAmp Optical 96-well plate, Lifetechnologies,
Carlsbad, CA, USA) containing 5 μl Single Cell Lysis Buffer and 0.5 μl Single Cell
DNaseI (from Single Cell lysis kit, Ambion, Carlsbad, CA, USA). Then, 2.5 μl
of RT reaction mix (iScript Advanced cDNA Synthesis kit for RT-qPCR, Bio-Rad,
Marnes-La-Coquette, France) was added to the single cell lysate. RT reaction
was performed according to manufacturer instructions. Droplet digital PCR
ampliﬁcation of EWSR1-FLI1 (FAM) and RPLP0 (VIC) was performed in 25 μl
reactions by adding the ddPCR Supermix for Probes No UDP (Bio-Rad), the FAM
probes and the VIC probes to the cDNA. Droplets were generated using the
QX100 Droplet Generator (Bio-Rad) with 50 μl Droplet Generation Oil (Bio-Rad)
and were thermocycled under the following conditions: 95 °C for 10 min, then
40 cycles of 94 °C for 30 s, 59 °C for 60 s, and ﬁnal enzyme deactivation at 98 °C
for 10 min. The individual droplets were analysed using the QX100 Droplet
Reader and Quantasoft software.
Immunohistochemistry on Ewing sarcoma tissue microarrays
(TMA)
Four different series of Ewing tumour tissue microarray were used in this study:
TMA1 containing 20 samples from CHR de Marseille Hopital de la Timone
(C Bouvier), TMA2 containing 67 samples from CHR de Tours (G De Pinieux),
TMA3 containing 23 samples from CHR de Lille (S Aubert), TMA4 containing 184
samples from University of Münster (Uta Dirksen/PROVABES). Parafﬁn-
embedded sections of each TMA were stained with rabbit LOX antibody
(PTGlab, #17958-1-AP, dil 1/100). Precise quantiﬁcation of tumour sample subset
was performed using Immunoratio ImageJ plugin.
Tail vein metastasis assay
Two million shA673-1c/GFP cells treated with 1 μg/ml of DOX during
10 days (EWSR1-FLI1low→high group) or untreated (EWSR1-FLI1high group)
were injected into the tail vein of eight female Severe Combined Immune
Deﬁciency mice for each group, 7-weeks old. A piece of each lung was
ﬁxed by immersion in 4% paraformaldehyde during 24 h, washed in 1X
PBS and steeped into a solution of 20% sucrose until full inﬁltration, then
embedded into optimal cutting temperature compound (Tissue-Tek,
Sakura, Villeneuve d'Ascq, France) and cryofreezed. All experimental
procedures and animal housing were performed in strict accordance with
the recommendations of the European and National Regulations for the
Protection of Vertebrate Animals used for Experimental and other Scientiﬁc
Purposes (facility license #C75-05-18) for care and use of laboratory
animals. All animal experiments were carried out under the supervision of
an investigator authorized by the French Competent Veterinary Authority.
Ewing cell lines, EWSR1-FLI1 transient and inducible inhibition by
shRNA
A673, SK-N-MC, EW7 and TC71 are patient-derived Ewing sarcoma cell
lines. The shA673-1c clone was generated as previously described.14 Cell
authentication was performed by comparison with STR proﬁling from
ATCC (A673, SK-N-MC), DSMZ (TC71) and COSMIC (EW7). Cells were
checked routinely by PCR for the absence of mycoplasma. The shSK-E17T
clone was generated with SK-N-MC cell line as previously described for
shA673-1c clone, but the H1 promoter-tet-O-shEF-1 cassette was cloned
into pTRIP/GPF lentiviral expression vector. The transient inhibition of
EWSR1-FLI1 was performed with lentiviral infection of pLKO lentiviral
expression vectors carrying shRNA targeting the 3′UTR of FLI1.
The shA673-1c/mCherry and shA673-1c/GFP clones were constructed by
lentiviral infection of the pCDH1-EF1-mcherry (a kind gift from Philippe
Benaroch, U932, Institut Curie, Paris, France) and the pCDH1-EF1-copGFP
plasmid (System Biosciences, Palo Alto, CA, USA) in shA673-1c clone.
Production of lentiviral particles
Packaging, production and titration of viral particles were performed as
described in Lee et al.49
ShRNA, primers and antibodies
ShRNA for EWSR1-FLI1 inhibition, and primers, antibodies for RT-qPCR,
western blot, IF and IHC experiments are detailed in Supplementary Table S3.
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